TrianglePhase I CB-NK-TGF-ßR2-/NR3C1- in rGBM (NCT04991870)
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM trial for Recurrent Gliosarcoma (NCT04991870). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Recurrent glioblastoma resists nearly everything, partly because it bathes itself in TGF-beta, which puts immune cells to sleep, and because patients' steroids quiet them further.
The idea: natural killer cells edited so that neither signal can reach them, delivered straight into the tumor.
At MD Anderson, natural killer cells from donated umbilical cord blood are expanded and gene-edited to remove two receptors: the TGF-beta receptor, and the receptor for glucocorticoid steroids. They are then injected through a small reservoir under the scalp directly into the tumor, every four weeks, up to eight. In some patients, a dose comes before planned surgery, so the removed tissue shows whether the cells arrived and survived.
Shiao-Pei Weathers leads it, from age twelve. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.